--- title: "Alzheimer Disease, Life Molecular LMT-01-01-22 | Sutter Health" description: "An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)" url: "https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research studies](https://www.sutterhealth.org/research/studies) / 4. Alzheimer Disease, Life Molecular LMT-01-01-22 # Alzheimer Disease LMT-01-01-22 This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy. ![Armen J Moughamian, M.D.](https://dyn.mktgcdn.com/p/RgCcTyeIvpMgOFqCDoSpyzraSuTlOsJQoDza3IdO-TU/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Armen J Moughamian, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/armen-j-moughamian-md-1049681097) ## Research topics - [Alzheimer's Disease](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Alzheimer%27s+Disease%5C%22%22) - [All Neuroscience](https://www.sutterhealth.org/research-search-results?query=%22%5C%22All+Neuroscience%5C%22%22) ## Related studies [View all studies](https://www.sutterhealth.org/research/studies) - Research study ### [Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)](https://www.sutterhealth.org/research/studies/alzheimers-disease-alz-net-1078067750) Alzheimer's National Registry for Treatment and Diagnostics (ALZ-NET) - Research study ### [Alzheimers/Cognitive Impairment NVI-039 AD](https://www.sutterhealth.org/research/studies/alzheimerscognitive-impairment-nvi-039-ad-1078067742) Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment due to Alzheimer’s Disease - Research study ### [Amyotrophic Lateral Sclerosis (ALS) CAPTURE](https://www.sutterhealth.org/research/studies/create-capture-1049141876) Clinical Procedures to Support Research in ALS (CAPTURE-ALS) - Research study ### [Chronic Inflammatory Demyelinating Polyneuropathy Registry VRCIDP 5166-Vitaccess-CIDP-01](https://www.sutterhealth.org/research/studies/chronic-inflammatory-demyelinating-polyneuropathy-registry-vrcidp-5166-vitaccess-cidp-01-2064309821) Vitaccess Real CIDP Registry: A Prospective International Observational Patient Registry in Chronic Inflammatory Demyelinating Polyneuropathy Linking Clinical and Patient-Reported Data 5166-Vitaccess-CIDP-01 - Research study ### [Parkinson's Disease Personalized Care Application iPD](https://www.sutterhealth.org/research/studies/parkinsons-disease-personalized-care-application-ipd-2015631341) Pilot study for Digital and Personalized care for Parkinson’s disease using Apple HealthKit (iPD study) [View all studies](https://www.sutterhealth.org/research/studies) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research studies","item":"https://www.sutterhealth.org/research/studies"},{"@type":"ListItem","position":4,"name":"Alzheimer Disease, Life Molecular LMT-01-01-22"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979#medicalwebpage","name":"Alzheimer Disease, Life Molecular LMT-01-01-22","description":"An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)","url":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979","inLanguage":"en-US","dateModified":"2026-05-19","publisher":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"medicalAudience":{"@type":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979#medicalobservationalstudy"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979#breadcrumblist"},"mentions":[{"@type":"Person","@id":"https://www.sutterhealth.org/find-provider/dr-armen-j-moughamian-1046247952#Person","name":"Armen J Moughamian, M.D.","url":"https://www.sutterhealth.org/research/investigators/armen-j-moughamian-md-1049681097","sameAs":"https://www.sutterhealth.org/find-provider/dr-armen-j-moughamian-1046247952"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalObservationalStudy","@id":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979#medicalobservationalstudy","name":"Alzheimer Disease LMT-01-01-22","alternateName":"Alzheimer Disease, Life Molecular LMT-01-01-22","url":"https://www.sutterhealth.org/research/studies/alzheimer-disease-life-molecular-lmt-01-01-22-1049141979","description":"This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.","healthCondition":[{"@type":"MedicalCondition","name":"Alzheimer's Disease"},{"@type":"MedicalCondition","name":"All Neuroscience"}]} ```